

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07H 5/04, 5/06, 19/00 C07H 21/00, 19/06	A1	(11) International Publication Number: WO 94/06810 (43) International Publication Date: 31 March 1994 (31.03.94)
(21) International Application Number: PCT/US93/08391		(74) Agents: MORIARTY, John, V. et al.; Woodard, Emhardt, Naughton, Moriarty & McNett, Bank One Center/Tower, Suite 3700, 111 Monument Circle, Indianapolis, IN 46204 (US).
(22) International Filing Date: 7 September 1993 (07.09.93)		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(30) Priority data: 07/946,971 16 September 1992 (16.09.92) US		Published <i>With international search report.</i>
(71)(72) Applicants and Inventors: BERGSTROM, Donald, Eugene [US/US]; 903 Fifth Street, West Lafayette, IN 47906 (US). ANDREWS, Philip, Charles [US/US]; NICHOLS, Ruthann [US/US]; 108 South Revena Boulevard, Ann Arbor, MI 48103 (US). ZHANG, Peiming [CN/US]; 2429-1A Neil Armstrong, West Lafayette, IN 47906 (US).		

(54) Title: OLIGONUCLEOTIDES HAVING UNIVERSAL NUCLEOSIDE SPACERS



(57) Abstract

Oligonucleotides are made having at least ten nucleosides, at least two of which are A, T, G or C and at least one is a universal nucleoside.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TC	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

OLIGONUCLEOTIDES HAVING UNIVERSAL NUCLEOSIDE SPACERS**Field of the Invention.**

The present invention relates generally to oligonucleotides, and more particularly to oligonucleotides 5 having universal nucleosides included therein.

Background to the Invention.

This invention was made with U.S. Government support under Grant #R01 GM45551 awarded by the National Institute of Health. The U.S. Government has certain rights in the 10 invention. The invention was also developed with support from Purdue University, the University of Michigan and the Walther Cancer Institute.

The chemical synthesis of oligonucleotides has had tremendous biological application over the past several 15 decades. The simultaneous development of rapid and efficient methods of synthesis, together with advances in molecular biology techniques, has led to an increasing demand for synthetic oligonucleotides. Oligonucleotides can serve a multitude of purposes, including use as hybridization probes 20 for DNA isolation, as primers in the enzymatic amplification of DNA, as mutagens for site-directed DNA alterations, and as sequencing primers.

A major use of synthetic oligonucleotides is the identification of naturally-occurring DNA sequences. The 25 efficient isolation of specific DNA sequences depends to a great extent on the ability to accurately identify the DNA or RNA sequence of interest. When amino acid sequence information is available, it is possible to approximately

-2-

deduce the nucleotide sequence and then synthesize an oligonucleotide that can be used to identify clones containing the desire sequence. This approach has been used very successful and is one of the most widely used methods 5 for identifying specific DNA or RNA sequences.

Due to redundancy in the genetic code, it is almost always impossible to precisely predict a unique nucleotide sequence from an amino acid sequence. Mixtures of oligonucleotides that take this redundancy into account must 10 be synthesized and used for screening potential DNA or RNA candidates. However, the potential ambiguities or mismatches present in the sequences of a highly degenerate oligonucleotide mixture can result in the identification of colonies which contain sequences that are unrelated to the 15 DNA or RNA sequence of interest. This may be partially overcome by modifying the stringency of the hybridization conditions. An additional problem occurs if the oligonucleotide mixture contains a large number of sequences. In that case, the correct sequence may be diluted 20 to the point that the mixture becomes ineffective.

Unfortunately, there is often no alternative to the use of a complex mixture of oligonucleotides. The design of longer, unique oligonucleotides making use of species-specific codon frequencies to increase the 25 probabilities of correct base pairing is not always an option. Frequently the use of protein sequence information to screen DNA or RNA sequences is seriously limited due to either high degeneracy or incomplete or uncertain protein sequence information.

One solution to the problem has been to seek bases that 30 would hybridize equally to more than one nucleic acid base and hence decrease the number of partially redundant probes required. This has led to the concept of a "universal base," a modified nucleic acid base that could base-pair with any of 35 the common bases: deoxyadenosine (A), deoxythymidine (T),

-3-

deoxycytidine (C) and deoxyguanosine (G). Reference herein to A, C, G and T is intended to additionally encompass the RNA analogs thereto, including uridine (U) as the analog to T. The use of a universal base should reduce the degeneracy 5 to 1 and still preserve the uniqueness of the probe.

Successful development of a universal base could greatly reduce the element of risk and enhance success in screening DNA libraries.

A variety of compounds have been investigated as 10 universal bases and examples of such compounds are shown in FIG. 1. For example, Milligan et al. proposed the use of either 1,2-dideoxyribofuranose or 1,2-dideoxy-1(C)-phenylribofuranose as a universal base in a paper published in 1984. Ikehara and Inaoka synthesized the 15 deoxyriboside of benzimidazole, and suggested its use in oligonucleotides.

Hypoxanthine, xanthine and guanine deoxyribonucleosides 20 have been evaluated for their ability to hybridize to each of the four DNA bases in nonadecamers. The ninth base from the 5' end was modified in the sequence 5'-CGATGTTAYTACATGAGAC-3' and binding to the four sequences 5'-GTCTCATGTANTAACATCG-3' (N = A, C, G or T) was determined. Each of the substitutions destabilized the duplex relative to a control in which a G-C base pair occurred at this position.

25 Although it has been widely promoted, deoxyinosine is not as discriminating in forming base pairs as is required for many applications and has not met widespread acceptance. Since its introduction in 1985 as a "universal base" there have been some reports of its successful use in DNA probes, 30 however many more studies have been published using oligonucleotide mixtures than using deoxyinosine - suggesting that the need for a truly universal base remains.

The feasibility of using 5-fluorodeoxyuridine (F) as a base analog has been examined in synthetic oligonucleotides. 35 The A-F base pair is actually more stable than an A-T base.

-4-

pair and increases the T_m 1°C above an A-T pair. A G-F base pair is essentially neutral. Unfortunately, the application of 5-fluoracil as a universal base is limited to pairing with A and G.


- 5 The introduction of a universal base would have numerous advantages. As has been stated, the total number of sequences in a degenerate oligonucleotide mixture would be reduced. This would increase the effective specific activity of the correct sequence by exactly the amount due to the reduction
10 in degeneracy. One of the limiting factors in the use of highly degenerate oligonucleotide mixtures as probes for screening DNA or RNA sequences is the reduction in effective specific activity of the correct probe sequence in the large population of incorrect oligonucleotide sequences.
- 15 Second, a universal base would promote a uniform distribution of oligonucleotides. For example, when all four bases are incorporated into an oligonucleotide during chemical synthesis, all four bases are not equally represented due to different rates of degradation and to
20 different degrees of phosphoramidite reactivity. This may cause under-representation of certain sequences in an oligonucleotide mixture.

- 25 A need therefore exists for oligonucleotides having universal bases at potentially degenerate positions so that the oligonucleotide will bond to ambiguous DNA or RNA sequences. The present invention addresses that need.


-5-

SUMMARY OF THE INVENTION

Briefly describing the present invention, there are provided novel oligonucleotides comprising at least ten nucleosides, wherein at least two different nucleosides are selected from the group consisting of A, T, C and G, and wherein at least one nucleoside is a universal nucleoside of the formula:



wherein in the first cyclic structure illustrated above:
 each R_n is H, OH, F or OCH_3 ;
 Z is a member of the group consisting of O, S and CH_2 ;
 15 and
 B is a second cyclic structure comprising a five-membered, cyclic base having at least two double bonds in one of its possible tautomeric forms, and further having an electron withdrawing group bonded thereto, said base with
 20 electron withdrawing group being represented by the formula:



wherein:
 25 said base with electron withdrawing group is bonded at X_4 to the second cyclic structure of the

-6-

nucleoside;

X_1 , X_3 and X_5 are each members of the group consisting of N, O, C, S and Se;

5 X_2 and X_4 are each members of the group consisting of N and C; and

W is a member of the group consisting of F, Cl, Br, I, O, S, OH, SH, NH_2 , NO_2 , $C(O)H$, $C(O)NHOH$, $C(S)NHOH$, NO, $C(NOCH_3)NH_2$, OCH_3 , SCH_3 , $SeCH_3$, ONH_2 , $NHOCH_3$, N_3 , CN, $C(O)NH_2$, $C(NOH)NH_2$, $CSNH_2$ and
10 CO_2H .

One object of the present invention is to provide oligonucleotides which include universal nucleosides at degenerate positions.

Further objects and advantages of the present
15 invention will be apparent from the following description.

-7-

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows various compounds which have been proposed as universal nucleosides in the prior art.

FIG. 2 shows nucleosides in which the cyclic oxygen of the sugar portion is replaced with S or CH₂.

FIG. 3 shows nucleosides in which the base portion is a heterocycle including O, S or Se.

FIG. 4 shows nucleosides in which the base portion is a pyrrole, diazole or triazole derivative.

FIG. 5 shows potentially useful phosphonucleotide intermediates for use in constructing oligonucleotides of the present invention.

FIG. 6 shows a universal nucleoside according to the present invention.

-8-


DESCRIPTION OF THE PREFERRED EMBODIMENT

For the purposes of promoting an understanding of the principles of the invention, reference will now be made to preferred embodiments and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the invention is thereby intended, such alterations and further modifications in the illustrated aspects of the invention, and such further applications of the principles of the invention as illustrated herein being contemplated as would normally occur to one skilled in the art to which the invention relates.

One aspect of the present invention relates to oligonucleotides comprising at least ten nucleosides, at least two of which are selected from the group consisting of A, T, C and G, and at least one nucleoside being a universal nucleoside. The incorporation of one or more universal nucleosides into the oligomer makes bonding to unknown bases possible and allows the oligonucleotide to match ambiguous or unknown nucleic acid sequences. In one preferred aspect, all of the common DNA nucleosides - deoxyadenosine (A), thymidine (T), deoxycytidine (C) and deoxyguanosine (G) - are combined with at least several of the universal nucleosides to make an oligonucleotide having at least 10 nucleosides therein.

Considering first the universal nucleoside portion of the present invention, the preferred nucleosides of the present invention include a first (sugar) portion and a second (base) portion. The first portion of the nucleoside can be represented by the formula:

-9-



5 wherein each R_n is H, OH, F or OCH_3 , and Z is a member of the group consisting of O, S and CH_2 .

Most commonly, the first (sugar) portion will be D-deoxyribose or D-ribose as found in naturally occurring ribonucleosides and deoxyribonucleosides. The Z atom of the 10 above formula will be O in these preferred cases.

Alternatively, the oxygen of this cyclic structure may be replaced by either S or CH_2 without unreasonably affecting the performance of the nucleoside in some applications.


Examples of nucleosides having a first "sugar" portion which 15 is substituted with S or CH_2 are shown in FIG. 2; additional examples of such compounds may be developed by those skilled in the art without undue experimentation.

A variety of substituents may be included at R_1 and/or R_2 . In particular, both R_1 and R_2 may be H as in the 20 case of D-deoxyribose. If one of those substituents is H and the other is OH the first (sugar) portion may be D-ribose as in naturally-occurring ribonucleosides. Alternatively, either or both of R_1 and R_2 may be substituted with F or OCH_3 . The use of fluorine substituted nucleosides has been 25 suggested by the prior art as in, for example, 2'-fluoro-2'-deoxyadenosine, which was incorporated into oligonucleotides by M. Ikehara and coworkers (Ikehara, 21 Heterocycles 75, 1984).

The second (base) portion "B" of the universal

-10-

nucleosides is preferably a five-membered, heterocyclic base having at least two double bonds in one of its possible tautomeric forms, and further having an electron withdrawing group bonded thereto. Preferred base portions are
5 represented by the formula:



As was mentioned above, X_1 , X_3 and X_5 are each
10 members of the group consisting of C, N, O, S and Se. In the universal nucleosides preferred in testing to date, X_1 , X_3 and X_5 are either C or N, with the most preferred compounds including at least one N. Alternative nucleosides including O, S or Se are shown in FIG. 3; additional
15 alternatives may be prepared by one skilled in the art without undue experimentation.

As was stated above, X_2 and X_4 are each preferably members of the group consisting of N and C. In the nucleosides most preferred in testing to date at least one of
20 these two atoms is N, although the exact location of the nitrogen may vary according to the particular application.

It is to be appreciated that there are some limitations as to which atoms can be located at X_1 , X_2 , X_3 and X_5 . In particular, when $X_4 = N$ and X_4 is the site of
25 the glycosidic bond, then X_1 , X_3 and X_5 can only be C or N, and X_2 must be C. O, S or Se can be tolerated at X_1 , X_3 and X_5 only when $X_4 = C$, and even in that case there can be no more than one of these atoms (O, S and Se) in the five-membered heterocyclic ring.

30 When N is included in the nucleoside, the base may be, for example, a pyrrole, diazole or triazole. Examples of such nucleosides are shown in FIG. 4, and can be prepared by

-11-

one skilled in the art without undue experimentation.

- The electron withdrawing group W is a member of the group consisting of F, Cl, Br, I, O, S, OH, SH, NH₂, NO₂, C(O)H, C(O)NHOH, C(S)NHOH, NO, C(NOCH₃)NH₂, OCH₃, SCH₃, SeCH₃, ONH₂, NHOCH₃, N₃, CN, C(O)NH₂, C(NOH)NH₂, CSNH₂ and CO₂H. NO₂ has been especially effective in experiments to date, and is particularly preferred for Sanger sequencing. C(O)NH₂ has also been particularly effective in certain applications.
- 10 A number of structural features of the preferred base portions should be mentioned. First, it is to be appreciated that the electron withdrawing group is bonded to the remainder of the base portion only at X₂. In some unsatisfactory prior art nucleosides, such as deoxyinosine, 15 the electron withdrawing group bonds to the remainder of the base portion at both X₂ and X₃ - which limits the ability of the base to assume a position necessary to optimize both hydrogen bonding and base stacking.
- Adding substituents at X₁, X₃ or X₅ may be 20 effective in some cases, although any substituents added at those positions must be small enough to avoid steric interference and must not prevent effective base stacking and bonding interactions. Small substituents which do not interfere with the coplanarity of the extended ring system 25 are preferred. X₁, X₃ or X₅ should be C if a substituent is added to that atom. Nucleosides in which such substituents are included at X₁, X₃ or X₅ are to be considered equivalent to the specifically disclosed nucleosides.
- 30 Preferably, the base-with-electron withdrawing group comprises an extended π system which favors base stacking interactions. Specifically, the preferred electron withdrawing groups enhance base stacking through interaction with adjacent pyrimidine and purine ring systems in a 35 polynucleotide double helix.

-12-

The universal nucleosides of the present invention accordingly preferably possess the following chemical and structural properties:


1. One or more donor or acceptor sites for hydrogen bonding
5 to A, C, G or T.
 2. Planar aromatic π system capable of stacking interactions with A, C, G and T in duplex or triplex nucleic acids.
 3. The molecule is sterically accommodated within duplex or
10 triplex nucleic acid, while at the same time maintaining both base stacking and hydrogen bonding interactions.
 4. At least one of the following derivatives of the universal nucleoside is chemically accessible and stable: a phosphoramidite substituted by a protecting group such as cyanoethyl; H-phosphonate; a phosphodiester in which one of the phosphorus substituents is a protecting group such as O-chlorophenyl; or a phosphite triester in which two of the substituents can function as either transient protecting groups or leaving groups for
15 phosphorus ester formation.
 5. The universal nucleoside, once incorporated into oligonucleotide under construction, is completely stable to the reagents and conditions of oligonucleotide synthesis as well as stable to oxygen, light and water.
20
- 25 The synthesis of oligonucleotides from their nucleosidal components is accomplished in a straightforward manner using standard protocols on commercial DNA synthesizers. In general, the synthesis of the oligonucleotide proceeds through a phosphorus-based intermediate. Such syntheses can
30 be accomplished by one skilled in the art without undue experimentation.
- Examples of useful phosphorus-containing nucleotide intermediates are shown in FIG. 5 and include phosphotriesters according to Sproat and Gait (1984);

-13-

phosphoramidites according to Beaucage and Caruthers (1981); H-phosphonates according to Froehler and Matteucci (1986); and phosphites according to Hasaka et al. (1991). The selection of an appropriate pathway to oligonucleotide 5 synthesis may be selected by one skilled in the art without undue experimentation.

The synthesis of 3-nitropyrrole deoxyribonucleoside (1) and its protected phosphoramidite (2) is outlined in Scheme 1 below. The two reactants, 3-nitropyrrole and 10 2-deoxy-3,5-di-O-p-toluoyl-D-erythro-pentofuranosyl chloride are prepared by literature methods.

SCHEME 1



-15-

EXAMPLE 1

Modified nucleosides designed to function as universal nucleic acid bases were synthesized and their suitability as constituents of oligonucleotide probes were determined in 5 physicochemical and molecular biological studies. As many as nine DNA bases of a 17-mer primer were replaced by 3-nitropyrrole deoxyribonucleoside without destroying the ability of the primer to initiate DNA synthesis.

The oligonucleotide sequences shown in Table 1 have been 10 synthesized and tested as primers for DNA synthesis. The synthetic oligonucleotides were used as primers for sequencing single-stranded DNA by the Sanger method. Sanger dideoxy sequencing was performed using the United States Biochemical (USB) Sequenase version 2.0 sequencing kit. The 15 DNA sequenced was a Hind III-Bluescript SK⁺ subclone of a Drosophila neural peptide gene described in Nichols et al. J. Biol. Chem. 263: 12167 (1988). The template DNA was either ssDNA or dsDNA, and oligonucleotides were purified using 20% acrylamide-8M urea eletrophoretic gels and size exclusion chromatography. Approximately 1 µgDNA was sequenced with 20 0.1 µg oligonucleotide according to conditions provided by the supplier using ³⁵S-dATP (Amersham). Aliquots of the sequencing reactions were electrophoresed on 6% acrylamide-8M urea sequencing gels after which the gel was dried and 25 exposed to Kodak XAR X-ray film.

The results indicate that proper sequencing was achieved by oligonucleotides of the present invention. In particular, it was shown that as many as nine bases in a 17-mer sequence can be substituted by 3-nitropyrrole and a readable 30 sequencing ladder obtained.

As previously stated, there are a variety of applications in addition to DNA sequencing for which the oligonucleotides of the present invention are particularly effective. For example, the use of such oligonucleotides in polymerase chain

-16-

reaction (PCR) techniques would be extremely beneficial. PCR is a powerful technique with many applications such as, for example, the screening of individuals for medically significant mutations.

5 Also, the oligonucleotides of the present invention may be effective for hybridization uses such as the screening of complex DNA or genomic libraries, the quantification of nucleic acids and the analysis of a Northern or Southern blot. The use of a universal nucleoside at the degenerate 10 sites would allow a single oligonucleotide to be used as a probe instead of a complex mixture.

It is also anticipated that the oligonucleotides of the present invention will find widespread applicability in both clinical and therapeutic settings. For example, DNA 15 hybridization assays have become an important clinical tool for diagnosis of many disease states. Because of variations in the genetic sequence of virtually all pathogenic viruses, probes containing oligonucleotides having universal bases would be particularly effective. Therapeutic applications 20 such as incorporation into triplex forming oligonucleotides and in antisense oligonucleotide therapeutics directed toward nucleic acid targets which have significant variability are also anticipated.

While the invention has been illustrated and described in 25 detail in the foregoing description, the same is to be considered as illustrative and not restrictive in character, it being understood that only the preferred embodiment has been shown and described and that all changes and modifications that come within the spirit of the invention 30 are desired to be protected.

-17-

Table 1. Modified Primers for Sanger Sequencing

Primer No.	Sequence
65	5'-CGT AAT CAG AAA ACA AT-3'
66	5'-CGT AAN CAN AAN ACN AT-3'
5	(256 - degenerate primer mixture)
67	5'-CGT AAI CAI AAI ACI AT-3'
72	5'-CGT AAM CAM AAM ACM AT-3'
73	5'-CGT AAT CAG AAA ACA MT-3'
74	5'-CGT AAT CAG AAA ACA AT-3'
10	(synthesized on a universal support)
75	5'-CGT AAT CAG AAA ACA AM-3'
	(synthesized on a universal support)
77	5'-CGT AAT CAG AAA MMM AT-3'
78	5'-CGT AAT CAG MMM MMM AT-3'
15	5'-CGT AAT C <u>A</u> G AAC ACA AT-3'
79	5'-CGT AAT CAG <u>A</u> AC AAC AT-3'
81	5'-CGT AAT CAG AAA A <u>C</u> G AT-3'
82	5'-CGT AAT CAG AAC <u>A</u> CG AT-3'
83	5'-CGT AAT MMM MMM MMM AT-3'
84	5'-CGT AAT CAG AAA ACA A <u>C</u> -3'
20	5'-CGT <u>A</u> AC CAA AAC ACG AT-3'
	I = deoxyinosine
	M = 3-nitropyrrole deoxyribonucleoside
	All underlined bases are mismatches to target sequence.


-18-

CLAIMS

We claim:

1. An oligonucleotide comprising at least ten nucleosides, including at least two different nucleoside members of the 5 group consisting of A, T, C and G, and wherein at least one nucleoside is a universal nucleoside of the formula:

10




wherein in the first cyclic structure illustrated above:

each R_n is H, OH, F or OCH₃;

Z is a member of the group consisting of O, S and CH₂;

and

- 15 B is a second cyclic structure comprising a five-membered, cyclic base having at least two double bonds in one of the possible tautomeric forms of the cyclic structure, and further having an electron withdrawing group bonded thereto, said base with electron withdrawing group 20 being represented by the formula:



wherein:

- 25 said base with electron withdrawing group is bonded at X₄ to the second cyclic structure of the

-19-

nucleoside;

X_1 , X_3 and X_5 are each members of the group consisting of N, O, C, S and Se;

5 X_2 and X_4 are each members of the group consisting of N and C; and

W is a member of the group consisting of F, Cl, Br, I, O, S, OH, SH, NH_2 , NO_2 , $C(O)H$, $C(O)NHOH$, $C(S)NHOH$, NO , $C(NOCH_3)NH_2$, OCH_3 , SCH_3 , $SeCH_3$, ONH_2 , $NHOCH_3$, N_3 , CN, $C(O)NH_2$, $C(NOH)NH_2$, $CSNH_2$ and
10 CO_2H .

2. An oligonucleotide according to claim 1 wherein at least four nucleosides are universal nucleosides of the formula of claim 1.

3. An oligonucleotide according to claim 2 wherein at least 15 eight nucleosides are said universal nucleosides of the formula of claim 1.

4. An oligonucleotide according to claim 1 wherein at least one nucleoside is A, at least one nucleoside is T, at least one nucleoside is C, and at least one nucleoside is G.

20 5. An oligonucleotide according to claim 1 wherein at least one universal nucleoside is a nucleoside of the formula of claim 1 wherein Z is O.

6. An oligonucleotide according to claim 1 wherein at least 25 one universal nucleoside is a nucleoside of the formula of claim 1 wherein each R_n is H.


7. An oligonucleotide according to claim 1 wherein at least one universal nucleoside is a nucleoside of the formula of claim 1 wherein R_1 is H and R_2 is OH.







-20-

8. An oligonucleotide according to claim 1 wherein at least one universal nucleoside is a nucleoside of the formula of claim 1 wherein R₁ is H and R₂ is F.
9. An oligonucleotide according to claim 1 wherein at least 5 one universal nucleoside is a nucleoside of the formula of claim 1 wherein R₁ is H and R₂ is OCH₃.
10. An oligonucleotide according to claim 1 wherein at least one universal nucleoside is a nucleoside of the formula of claim 1 wherein B is a substituted pyrrole.
- 10 11. An oligonucleotide according to claim 1 wherein at least one universal nucleoside is a nucleoside of the formula of claim 1 wherein B is a substituted imidazole.
12. An oligonucleotide according to claim 1 wherein at least one universal nucleoside is a nucleoside of the formula of 15 claim 1 wherein B is a substituted triazole.
13. An oligonucleotide according to claim 1 wherein at least one universal nucleoside is a nucleoside of the formula of claim 1 wherein X₄ is N.
14. An oligonucleotide according to claim 13 wherein at least 20 one universal nucleoside is a nucleoside of the formula of claim 1 wherein W is NO₂.
15. An oligonucleotide according to claim 1 wherein at least one universal nucleoside is a nucleoside of the formula of claim 1 wherein W is NO₂.


-21-

16. A nucleoside of the formula:




Analogs evaluated as potential universal nucleosides

2/6



(2.1)



(2.2)

Fig. 2

3/6





Fig.3

4/6






Fig.4

Phosphotriester Method



Phosphoramidite



H-phosphonate





Fig. 5

6/6




Fig. 6

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/08391

A. CLASSIFICATION OF SUBJECT MATTER

IPC(S) : C07H 5/04, 5/0619/00, 21/00, 19/06

US CL : 536/18.7, 22.1, 26.1, 26.9, 28.6, 28.7, 28.8, 28.9

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/18.7, 22.1, 26.1, 26.9, 28.6, 28.7, 28.8, 28.9

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Nucleosides and Nucleotides, Volume 7, Number 3, issued 1988, Ramasamy et al, "Synthesis of Brunfelsiamidine Ribonucleoside and Certain Related Compounds By the Stereospecific Sodium Salt Glycosylation Procedure", pages 385-392, see entire document.	1-15
Y	Nucleic Acids Research, Volume 18, number 5, issued 1990, Dawson et al, "Sythesis and Characterization of a Ribavirin-3',5'-Phosphate Pentadecamer Homoribopolymer Bearing a 5'-amino Tether Group and a 3'-thymidine", pages 1099-1102, see entire document.	16

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be part of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 18 October 1993	Date of mailing of the international search report NOV 02 1993
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. NOT APPLICABLE	Authorized officer L. LANKFORD <i>R. Krueger Jr.</i> Telephone No. (703) 308-0196